Cargando…

The effectiveness and safety of full-dose versus half-dose corticosteroid plus renin-angiotensin system blockers for IgA nephropathy

BACKGROUND: Observational studies suggest that patients with immunoglobulin A nephropathy (IgAN) showed good responses to corticosteroids (CS) but experienced severe adverse effects. The authors conducted a cohort study to evaluate the effectiveness and safety of half-dose CS plus renin-angiotensin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Li, Ren, Daijin, Huang, Tianlun, Liu, Xin, Xu, Gaosi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6854762/ https://www.ncbi.nlm.nih.gov/pubmed/31762966 http://dx.doi.org/10.1177/2040622319887875

Ejemplares similares

Clinical efficacy and safety of full-dose versus half-dose corticosteroids plus leflunomide for IgA nephropathy
por: Li, Yebei, et al.
Publicado: (2021)

Use of low-dose sulodexide in IgA nephropathy patients on renin–angiotensin system blockades
por: Yang, Byeong Yun, et al.
Publicado: (2012)

Comparison of combined leflunomide and low-dose corticosteroid therapy with full-dose corticosteroid monotherapy for progressive IgA nephropathy
por: Min, Lulin, et al.
Publicado: (2017)

Supportive Management of IgA Nephropathy With Renin-Angiotensin Blockade, the AIIMS Primary IgA Nephropathy Cohort (APPROACH) Study
por: Bagchi, Soumita, et al.
Publicado: (2021)

Increasing prescription of renin–angiotensin–aldosterone system blockers associated with improved kidney prognosis in Korean IgA nephropathy patients
por: Park, Sehoon, et al.
Publicado: (2020)

Single versus dual blockade of the renin-angiotensin system in patients with IgA nephropathy
por: Lennartz, David Paul, et al.
Publicado: (2020)

An Update on Targeted Treatment of IgA Nephropathy: An Autoimmune Perspective
por: Huang, Xin, et al.
Publicado: (2021)

Prominent hyperplasia of renin-producing juxtaglomerular apparatus after chronic and complete blockade of the renin-angiotensin system in adult IgA nephropathy
por: Abe, Michiaki, et al.
Publicado: (2015)

New-onset IgA nephropathy following COVID-19 vaccination
por: Ma, Yaohui, et al.
Publicado: (2022)

Severity of arterial and/or arteriolar sclerosis in IgA nephropathy and the effects of renin–angiotensin system inhibitors on its prognosis
por: Sugiura, Naoko, et al.
Publicado: (2021)

The role of mononuclear phagocyte system in IgA nephropathy: pathogenesis and prognosis
por: Liu, Yiwen, et al.
Publicado: (2023)

Use of low-dose sulodexide in IgA nephropathy patients on renin–angiotensin system blockades [Volume 31, Issue 3, September 2012, Pages 163–169]
por: Yun Yang, Byeong, et al.
Publicado: (2013)

Meta-analysis of effect of renin–angiotensin–aldosterone system blockers on contrast-induced nephropathy
por: Wang, Weidong, et al.
Publicado: (2020)

Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers
por: Danser, A.H. Jan, et al.
Publicado: (2020)

Corticosteroids in Patients with IgA Nephropathy and Severe Chronic Renal Damage
por: Pozzi, Claudio, et al.
Publicado: (2012)

Fixed-Dose Combinations of Renin–Angiotensin System Inhibitors and Calcium Channel Blockers in the Treatment of Hypertension: A Comparison of Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors
por: Hsiao, Fu-Chih, et al.
Publicado: (2015)

Efficacy and Safety of Renin-Angiotensin Aldosterone System Inhibitor in Patients with IgA Nephropathy: A Meta-Analysis of Randomized Controlled Trials
por: ZHAO, Yu, et al.
Publicado: (2019)

High-sensitive cardiac troponin for the diagnosis of acute myocardial infarction in different chronic kidney disease stages
por: Ren, Daijin, et al.
Publicado: (2021)

Renin-angiotensin system blockers and COVID-19
por: Vidal-Petiot, Emmanuelle, et al.
Publicado: (2021)

Corticosteroid Treatment Influences TA-Proteinuria and Renal Survival in IgA Nephropathy
por: Sarcina, Cristina, et al.
Publicado: (2016)

Severe Adverse Effects Associated With Corticosteroid Treatment in Patients With IgA Nephropathy
por: Cai, Qingqing, et al.
Publicado: (2017)

The Role of IgA in the Pathogenesis of IgA Nephropathy
por: Perše, Martina, et al.
Publicado: (2019)

Efficacy and Safety of Glycosides of Tripterygium wilfordii Combined with Renin-Angiotensin System in the Treatment of IgA Nephropathy: A Systematic Review and Meta-Analysis
por: Chen, Ming, et al.
Publicado: (2022)

The response of the Oxford classification to steroid in IgA nephropathy: a systematic review and meta-analysis
por: Yang, Pingping, et al.
Publicado: (2017)

Significance of Urinary Full-Length Megalin in Patients with IgA Nephropathy
por: Seki, Takuto, et al.
Publicado: (2014)

Comparative analysis between the safety and efficacy of oral corticosteroids versus corticosteroids pulse therapies in IgA nephropathy
por: Wang, Yu, et al.
Publicado: (2023)

Validation of the revised Oxford classification for IgA nephropathy considering treatment with corticosteroids/immunosuppressors
por: Moriyama, Takahito, et al.
Publicado: (2020)

IgA Vasculitis and IgA Nephropathy: Same Disease?
por: Pillebout, Evangeline
Publicado: (2021)

Comparative Efficacy and Safety of Therapies in IgA Nephropathy: A Network Meta-analysis of Randomized Controlled Trials
por: Yang, Pingping, et al.
Publicado: (2018)

Comparative efficacy of different renin angiotensin system blockade therapies in patients with IgA nephropathy: a Bayesian network meta-analysis of 17 RCTs
por: Huo, Zhihao, et al.
Publicado: (2021)

Plasma exosomal IRAK1 can be a potential biomarker for predicting the treatment response to renin-angiotensin system inhibitors in patients with IgA nephropathy
por: Wu, Jianping, et al.
Publicado: (2022)

Retracted: Efficacy and Safety of Glycosides of Tripterygium wilfordii Combined with Renin-Angiotensin System in the Treatment of IgA Nephropathy: A Systematic Review and Meta-Analysis
por: International, Emergency Medicine
Publicado: (2023)

Experimental IgA nephropathy
Publicado: (1979)

Sulodexide in IgA nephropathy
Publicado: (2013)

T lymphocytes in IgA nephropathy
por: Tang, Yuyan, et al.
Publicado: (2020)

Secondary IgA Nephropathy Shares the Same Immune Features With Primary IgA Nephropathy
por: Wang, Manliu, et al.
Publicado: (2019)

Validation of the International IgA Nephropathy Prediction Tool in the Greek Registry of IgA Nephropathy
por: Papasotiriou, Marios, et al.
Publicado: (2022)

An adolescent girl diagnosed with IgA nephropathy following the first dose of the COVID-19 vaccine
por: Okada, Mari, et al.
Publicado: (2022)

Leflunomide plus low-dose prednisone in patients with progressive IgA nephropathy: a multicenter, prospective, randomized, open-labeled, and controlled trial
por: Ni, Zhaohui, et al.
Publicado: (2021)

Possible beneficial association between renin-angiotensin-aldosterone-system blockade usage and graft prognosis in allograft IgA nephropathy: a retrospective cohort study
por: Park, Sehoon, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ao7llgqnvc23k2f26g222leo9k